OWC Pharmaceutical Research Corp. - Quarter Report: 2015 June (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 10-Q
___________________
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2015
Commission file number 0-54856
OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant in its Charter)
Delaware | 98-0573566 |
(State or other Jurisdiction of Incorporation) | (IRS Employer Identification No.) |
22 Shaham Steet, P.O. Box 8324, Petach Tikva, 4918103, Israel
(Address of Registrants Principal Executive Offices and Principal Place of Business)
Registrant's Telephone Number, Including Area Code: Phone: +972 (0) 3-758-2657
Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act) or a smaller reporting company .
Large accelerated filer ¨ | Accelerated filer ¨ | Non-Accelerated filer ¨ | Smaller reporting company x |
On August 17, 2015, the Registrant had 80,654,176 shares of common stock outstanding.
Item |
Description |
Page |
|||
---|---|---|---|---|---|
PART I - FINANCIAL INFORMATION |
|||||
ITEM 1. | FINANCIAL STATEMENTS - UNAUDITED. | 3 | |||
Consolidated Balance Sheets | 3 | ||||
Consolidated Statements of Operations | 4 | ||||
Consolidated Statements of Comprehensive Loss | 5 | ||||
Consolidated Statements of Cash Flows | 6 | ||||
Notes to Unaudited Interim Consolidated Financial Statements | 7 | ||||
ITEM 2. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS. | 13 | |||
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. | 18 | |||
ITEM 4. | CONTROLS AND PROCEDURES. | 18 | |||
PART II - OTHER INFORMATION |
|||||
ITEM 1. | LEGAL PROCEEDINGS. | 18 | |||
ITEM 1A. | RISK FACTORS. | 18 | |||
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. | 18 | |||
ITEM 3. | DEFAULT UPON SENIOR SECURITIES. | 18 | |||
ITEM 4. | MINE SAFETY DISCLOSURE. | 18 | |||
ITEM 5. | OTHER INFORMATION. | 19 | |||
ITEM 6. | EXHIBITS. | 19 |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents
OWC Pharmaceutical Research Corp. | ||||
Consolidated Balance Sheets | ||||
At June 30, 2015 and December 31, 2014 | ||||
Back to Table of Contents | ||||
June 30, 2015 | ||||
(Unaudited) | December 31, 2014 | |||
ASSETS | ||||
Current assets: | ||||
Cash | $ | 799,374 | $ | 1,469,267 |
Other current assets | 12,903 | 24,091 | ||
Total current assets | 812,277 | 1,493,358 | ||
Property and equipment, net | 28,109 | 29,454 | ||
Total Assets | $ | 840,386 | $ | 1,522,812 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current liabilities: | ||||
Accounts payable - trade | $ | 52,559 | $ | 16,523 |
Accrued expenses | 2,947 | 43,643 | ||
Advances and accounts payable to related parties | - | 138 | ||
Total current liabilities | 55,506 | 60,304 | ||
Total liabilities | 55,506 | 60,304 | ||
Stockholders' equity: | ||||
Preferred stock, $0.00001 par value; 20,000,000 shares authorized; no shares issued and outstanding | - | - | ||
Common stock, $0.00001 par value; 500,000,000 shares authorized; and | ||||
80,320,843 and 78,429,241 issued and outstanding at June 30, 2015 and December 31, 2014, respectively | 803 | 784 | ||
Additional paid in capital | 8,292,838 | 8,000,847 | ||
Common stock subscriptions receivable | (651,730) | (651,730) | ||
Common stock subscription payable | 50,000 | - | ||
Accumulated deficit | (6,907,908) | (5,893,878) | ||
Accumulated other comprehensive income | 877 | 6,485 | ||
Total stockholders' equity | 784,880 | 1,462,508 | ||
Total liabilities and stockholders' equity | $ | 840,386 | $ | 1,522,812 |
See notes to unaudited interim consolidated financial statements. |
OWC Pharmaceutical Research Corp. | ||||||||
Consolidated Statements of Operations | ||||||||
For the Three and Six-Months Ended June 30, 2015 and 2014 | ||||||||
(Unaudited) | ||||||||
Back to Table of Contents | ||||||||
For the three |
For the three |
For the six |
For the six |
|||||
months ended |
months ended |
months ended |
months ended |
|||||
June 30, 2015 |
June 30, 2014 |
June 30, 2015 |
June 30, 2014 |
|||||
Revenues |
$ |
- |
$ |
- |
$ |
- |
$ |
- |
Expenses | ||||||||
General and administrative | 532,815 |
(106,930) |
824,090 |
365,212 |
||||
Research and development | 76,612 |
- |
189,940 |
- |
||||
(Loss) from operations | (609,427) | 106,930 | (1,014,030) | (365,212) | ||||
Other income (expense): | ||||||||
Interest expense | - | (86) | - | (2,923) | ||||
Amortization of debt discount | - | - | - | (34,034) | ||||
Total other (expense) | - |
(86) |
- |
(36,957) |
||||
Total costs and expenses | (609,427) | 106,844 | (1,014,030) | (402,169) | ||||
Net income (loss) before income taxes | (609,427) | 106,844 | (1,014,030) | (402,169) | ||||
Income tax | - |
- |
- |
- |
||||
Net income (loss) | $ |
(609,427) |
$ |
106,844 |
$ |
(1,014,030) | $ |
(402,169) |
Basic and diluted per share amounts: | ||||||||
Basic and diluted net loss | $ |
(0.02) |
$ |
0.00 |
$ |
(0.02) |
$ | (0.01) |
Weighted average shares outstanding (basic and diluted) | 40,129,063 |
47,666,243 |
$ |
58,799,819 |
$ | 38,562,849 |
||
See notes to unaudited interim financial statements. |
OWC Pharmaceutical Research Corp. | ||||||||
Consolidated Statements Comprehensive Loss | ||||||||
For the Three and Six Months Ended June 30, 2015 and 2014 | ||||||||
(Unaudited) | ||||||||
Back to Table of Contents | ||||||||
For the three months | For the three months | For the six months | For the six months | |||||
ended June 30, 2015 | ended June 30, 2014 | ended June 30, 2015 | ended June 30, 2014 | |||||
Net loss | $ | (609,427) | $ | 106,844 | $ | (1,014,030) | $ | (402,169) |
Other comprehensive income, net of tax: | ||||||||
Foreign currency translation adjustments | (650) | - | (5,608) | - | ||||
Total other comprehensive income, net of tax | (650) | - | (5,608) | - | ||||
Comprehensive loss | $ | (610,077) | $ | 106,844 | $ | (1,019,638) | $ | (402,169) |
See notes to unaudited interim consolidated financial statements. |
OWC Pharmaceutical Research Corp. | ||||
For the Six Months Ended June 30, 2015 and 2014 |
||||
(Unaudited) | ||||
For the six |
For the six |
|||
months ended |
months ended |
|||
June 30, 2015 |
June 30, 2014 |
|||
Cash flows from operating activities: |
||||
Net loss | $ |
(1,014,030) |
$ |
(402,169) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Amortization of debt discount | - | 34,034 | ||
Depreciation | 4,524 | - | ||
Common stock issued for services | 241,170 | 326,000 | ||
Fair value of warrants issued for services | 10,839 | - | ||
Changes in net assets and liabilities: | ||||
(Increase) decrease in accounts receivable | 2,612 | - | ||
(Increase) decrease in accounts receivable - related party | 11,188 | - | ||
Advances and accounts payable to related parties | 138 | - | ||
Increase (decrease) in accounts payable | 35,762 | - | ||
Increase (decrease) in accrued expenses | (40,697) |
2,950 |
||
Cash used in operating activities | (751,106) |
(39,212) |
||
Cash flow from investing activities: | ||||
Purchase of equipment | (3,179) | - | ||
Cash used in investing activities | (3,179) |
- |
||
Cash flow from financing activities: | ||||
Proceeds from issuance of common stock | 90,000 | 868,800 | ||
Proceeds of debt borrowings | - | 14,500 | ||
Cash provided by financing activities | 90,000 |
883,300 |
||
Foreign currency translation | (5,608) |
- |
||
Change in cash | (669,893) |
844,088 |
||
Cash - beginning of period | 1,469,267 |
2,469 |
||
Cash - end of period | $ |
799,374 |
$ |
846,557 |
Supplement cash flow information: | ||||
Non-cash transactions: | ||||
Debt and accrued interest converted to equity | $ | - | $ | 130,849 |
See notes to unaudited interim financial statements. |
OWC Pharmaceutical Research Corp.
Notes to Unaudited Interim
Consolidated Financial Statements
June 30, 2015
Back to
Table of Contents
1. The Company and Significant Accounting Policies
Organizational Background: OWC Pharmaceutical Research Corp. ("OWCP" or the "Company") is a Delaware corporation and was incorporated under the laws of the State of Delaware on March 7, 2008. The Company is engaged in two distinct business activities: (i) work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the "Device"); and (ii) research and development of Cannabis-based medical products for the treatment of a variety of medical conditions and/or diseases such as multiple myeloma, psoriasis, PTSD, migraines and a unique delivery system.
The accompanying financial statements of OWCP were prepared from the accounts of the Company under the accrual basis of accounting. Certain amounts in the financial statements have been reclassified to conform to the current presentation. The reclassifications had no effect on the reported net loss.
Basis of Presentation: The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.
Principles of Consolidation: The financial statements include the accounts of OWC Pharmaceutical Research Corp. and its wholly owned subsidiary One World Cannabis, Inc. (OWC). All significant inter-company balances and transactions have been eliminated.
Significant Accounting Policies
Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at June 30, 2015 and December 31, 2014.
Property and Equipment: New property and equipment are recorded at cost. Property and equipment included in the bankruptcy proceedings and transferred to the Trustee had been valued at liquidation value. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 5 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place.
Valuation of Long-Lived Assets: We review the recoverability of our long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on our ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Our primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.
Foreign Currency: Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of other comprehensive income (loss) within stockholders' equity.
Stock Based Compensation: Stock-based awards are accounted for using the fair value method in accordance with ASC 718, Share-Based Payments. Our primary type of share-based compensation consists of stock options. We use the Black-Scholes option pricing model in valuing options. The inputs for the valuation analysis of the options include the market value of the Company's common stock, the estimated volatility of the Company's common stock, the exercise price of the warrants and the risk free interest rate.
Accounting For Obligations And Instruments Potentially To Be Settled In The Company's Own Stock: We account for obligations and instruments potentially to be settled in the Company's stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This issue addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company's own stock.
Fair Value of Financial Instruments: FASB ASC 825, "Financial Instruments," requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At June 30, 2015 and December 31, 2014, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Fair Value Measurements: The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are:
Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
Level 2: Inputs to the valuation methodology include:
- Quoted prices
for similar assets or liabilities in active markets;
- Quoted prices for
identical or similar assets or liabilities in inactive markets;
- Inputs
other than quoted prices that are observable for the asset or liability;
- Inputs that are derived principally from or corroborated by observable
market data by correlation or other means.
If the asset or liability has
a specified (contractual) term, the level 2 input must be observable for
substantially the full term of the asset or liability.
Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
The assets or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The following table presents assets that were measured and recognize at fair value on June 30, 2015 and December 31, 2014 and the year then ended on a recurring basis:
Fair Value Measurements at June 30, 2015 | ||||||||
Quoted Prices in Active | Significant Other | Significant | ||||||
Markets for Identical Assets | Observable Inputs | Unobservable Inputs | ||||||
Total |
(Level 1) |
(Level 2) |
(Level 3) |
|||||
None | $ |
- | $ |
- |
$ |
- |
$ |
- |
Total assets at fair value | $ |
- |
$ |
- |
$ |
- |
$ |
- |
Fair Value Measurements at December 31, 2014 | ||||||||
Quoted Prices in Active | Significant Other | Significant | ||||||
Markets for Identical Assets | Observable Inputs | Unobservable Inputs | ||||||
Total |
(Level 1) |
(Level 2) |
(Level 3) |
|||||
None | $ |
- | $ |
- |
$ |
- |
$ |
- |
Total assets at fair value | $ |
- |
$ |
- |
$ |
- |
$ |
- |
When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the fiscal periods ended June 30, 2015 and December 31, 2014, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels.
Earnings per Common Share: We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Income Taxes: We have adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.
We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.
Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset.
Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate.
In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be.
ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Uncertain Tax Positions: When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Our federal and state income tax returns are open for fiscal years ending on or after December 31, 2010. We are not under examination by any jurisdiction for any tax year. At June 30, 2015 we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required under FASB ASC 740-10.
Recent Accounting Pronouncements
In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-03, "Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. Currently, debt issuance costs are recognized as deferred charges and recorded as other assets. The guidance is effective for annual and interim periods beginning after December 15, 2015 with early adoption permitted and is to be implemented retrospectively. Adoption of the new guidance will only affect the presentation of the Company's consolidated balance sheets and will have no impact to our financial statements.
Management does not anticipate that the adoption of these standards will have a material impact on the financial statements.
The Financial Statements presented herein have been prepared by us in accordance with the accounting policies described in our December 31, 2014 Annual Report and should be read in conjunction with the Notes to Financial Statements which appear in that report.
The preparation of these financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related intangible assets, income taxes, insurance obligations and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions.
In the opinion of management, the information furnished in these interim financial statements reflects all adjustments necessary for a fair statement of the financial position and results of operations and cash flows as of and for the three and six-month periods ended June 30, 2015 and 2014. All such adjustments are of a normal recurring nature. The Financial Statements do not include some information and notes necessary to conform to annual reporting requirements.
2. Stockholders' Equity
Common Stock
Stock Issued for Cash:
In connection with a private placement of 10,000,000 shares of common stock in February of 2015 we sold 800,000 shares to one investor for the offering price of $0.05 per share that resulted in total proceeds of $40,000. During 2015, we also received $50,000 through a placement of common stock units. Those units were sold at $0.15 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. We are obligated to issue 333,333 shares to one investor of this offering. The $50,000 received through the unit offering is carried as subscription payable in stockholders' equity at June 30, 2015. The related warrants are exercisable at $0.25 and expire on December 31, 2016. During the period ended June 30, 2015, the Company cancelled 500,000 shares of common stock previously issued for services.
Stock Issued for Services:
During the interim period ended June 30, 2015 we issued 1,091,602 shares of our common stock to unrelated parties as payment for services. The shares were valued at the closing price as of the date of the agreements (ranging from $0.19 to $0.25) and resulted in full recognition of $241,170 in consulting services expense.
Historical Activity in 2014:
Stock Issued upon conversion of debt- On July 1, 2014 we issued 179,300 shares of our common stock in settlement of $1,500 in convertible note payable plus associated accrued interest of $293. The conversion occurred within the terms of the promissory note and no gain or loss resulted. On February 28, 2014 we issued 13,084,000 shares of our common stock in settlement of $114,414 in convertible note payable plus associated accrued interest of $16,435. The conversion occurred within the terms of the promissory note and no gain or loss resulted.
Stock Issued for Services:
During the interim period ended September 30, 2014 we issued 300,000 shares of our common stock to an unrelated party as payment for services. We also issued 400,000 shares to two former officers and directors of the company as part of a severance agreement. The shares were valued at the closing price as of the date of the agreements ($0.25 and $0.28, respectively) and resulted in full recognition of $187,000 in consulting services expense. During the interim periods ended on or before June 30, 2014 we issued 9,208,600 shares of our common stock to seven unrelated parties as payment for services. The shares were valued at the closing price as of the date of the agreement ($0.05) and resulted in full recognition of $481,430 in consulting services expense. In June we cancelled 3,108,600 of these shares valued at $155,430 resulting in $305,000 in consulting expense through September 30, 2014.
Options Issued for services:
During the interim period ended September 30, 2014 we issued 14,350,000 common stock options. 350,000 of those options valued at $82,640 were granted to former related parties while 14,000,000 options valued at $3,774,496 were granted for services provided by unrelated parties.
The fair value of the options was estimated at the date of grant using the Black-Sholes-Merton pricing model. The Black-Sholes-Merton pricing model assumptions used are as follows: expected dividend yield of 0%; risk-free interest rate of 0.47% to 0.49%; expected volatility of 241%, and warrant term of two years.
Stock Issued for cash-In connection with a private placement of 10,000,000 shares of common stock in March and April of 2014 we sold 4,700,000 shares to six investors for the offering price of $0.005 per share that resulted in total proceeds of $23,500. During 2014 we received $1,164,300 through a placement of common stock units. Those units were sold at $0.09 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. We issued 12,936,662 shares through September 30th to 22 investors of this offering. The warrants are exercisable at $0.16 and expire in June, 2015. During 2014 we received $554,200 through a placement of common stock units. Those units were sold at $0.15 per unit. Each unit consisted of one share of common stock and one warrant to purchase common stock. We issued 3,694,666 shares through September 30th to 4 investors of this offering. The warrants are exercisable at $0.16 and expire in June 2015.
Warrants
As part of the 2015 unit offering the Company issued a total of 333,333 warrants to purchase up to 333,333 shares of common stock at $0.25 per share.
The relative fair value of the warrants attached to the common stock issued was estimated at the date of grant using the Black-Sholes-Merton pricing model. The relative fair value of the attached to the common stock component is $26,416 and the relative fair value of the warrants is $23,584 as of the grant date.
In February, 2015 we issued 64,935 warrants for services. The warrants are exercisable at $0.25 and expire February 23, 2016. We used the Black-Scholes-Merton pricing model and inputs described below to estimate the fair value of $10,839.
The Black-Sholes-Merton pricing model assumptions used are as follows: expected dividend yield of 0%; risk-free interest rate of 0.10%-.0.11%; expected volatility of 242%, and warrant exercise period based upon the stated terms.
3. Related Party Transactions Not Disclosed Elsewhere
Due Related Parties: Amounts due related parties totaled $0 at June 30, 2015 and $138 at December 31, 2014, respectively. Accounts receivable from related parties was $15,919 at June 30, 2015 and $0 at December 31, 2014.
4. Notes Payable
Unsecured Notes Payable Without Conversion Rights
During 2014, the Company signed a series of three new unsecured promissory notes with unrelated parties for an aggregate of $14,500. The notes bear interest at 1% per annum and are due one year from the date of issuance. The notes were paid in full in 2014.
Unsecured Notes Payable With Conversion Rights
On February 28, 2014 eleven holders of convertible notes with an aggregate principal balance of $114,414 and accrued interest of $16,435 converted their notes and accrued interest into 13,084,000 shares of common stock. Upon conversion, $34,034 of unamortized discount arising from the previously recorded beneficial conversion feature was recognized as additional interest expense. The conversion occurred within the terms of the promissory note and no gain or loss resulted.
5. Future Commitment and Issuance of Warrants
On March 5, 2013, the Company and GUMI Tel Aviv Ltd, a major, privately-held Israeli technology company ("GUMI"), entered into development/manufacturing/marketing agreement ("GUMI Agreement"). GUMI is engaged in the manufacture, import/export, marketing and install industrial equipment and designing technical solutions.
Pursuant to the GUMI Agreement, GUMI agreed to: (i) complete the development of the Prototype of the Patented Device; (ii) manufacture the commercial model(s) of the Patented device; and (iii) market the commercial model(s) of the Patented Device.
In consideration for developing the Prototype and manufacturing and marketing/distributing commercial models of the Patented Device as well as incurring all related costs and expenses in connection therewith, the Company shall compensate GUMI as follows: (i) upon the execution of the GUMI Agreement, the Company granted GUMI warrants (the "Warrants") exercisable to purchase 200,000 shares of the Company's common stock ("Warrant Shares") at an exercise price of USD$0.05 per share (the "Exercise Price"); (ii) upon completion of the Prototype, granting GUMI additional Warrants to purchase 200,000 additional Warrant Shares at the Exercise Price; and (iii) upon completion of a Commercial Device ready for manufacture and sale, granting GUMI additional Warrants to purchase 200,000 additional Warrant Shares at the Exercise Price. The Warrants shall expire 3 years from the date of each grant and shall be subject to adjustment in the event of any recapitalization of the Company's capital stock.
In addition to the consideration represented by the grant of Warrants, the Agreement further provides that following commencement of sale of the Commercial Device and until such time that GUMI has recouped all costs and expenses that it has incurred and paid in connection with the completion of development of the Prototype and the manufacture of the Commercial Device ("Date of Recoupment"), one hundred (100%) percent of the net sales revenues shall be paid and distributed to GUMI. On and after the Date of Recoupment, net sales revenues shall be paid sixty-five (65%) percent to GUMI and thirty-five (35%) percent to the Company.
The Company recorded $107,074 in fiscal year 2013 in expenses related to 600,000 vested warrants previously granted to GUMI Tel Aviv Ltd. The warrants were valued using the Black-Scholes option pricing model. The inputs for the valuation analysis of the warrants include the market value of the Company's common stock were as follows: the estimated volatility of the Company's common stock used in the Black-Scholes option pricing model was 318%, the exercise price and the risk free interest rate used were $0.05 and 0.36%, respectively. All warrants are fully vested.
6. Going Concern
The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of June 30, 2015, the cash resources of the Company were insufficient to meet its current business plan. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of asset or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.
7. Subsequent Events
In July 2015, the Company issued the previously subscribed to 333,333 shares, which were recorded as stock payable a of June 30, 2015. There were no other subsequent events following the period ended June 30, 2015 and throughout the date of the filing of Form 10-Q.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATION Back to Table of Contents
The following discussion contains forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use of words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. From time to time, we also may provide forward-looking statements in other materials we release to the public.
Plan of Operations
We are engaged in three distinct business sectors and we may require additional capital to implement our business plan and fund our operations.
Our three distinct business operations are:
(i) continuing to work with GUMI
to commercialize and market the Company's Electromagnetic Percussion Device (the
"Device"); and
(ii) research and development of cannabis-based medical
products for the treatment of a variety of medical conditions such as multiple
myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD) and
migraine, and
(iii)
consulting services to companies and governmental agencies with respect to
complex international medical cannabis protocols and regulations.
We have not yet commenced any significant activities related to our consulting services.
In 2008, we acquired the patent for our Device and from 2008 until 2011, we devoted our limited resources and efforts to the development of our Device. During late 2011 and into 2012, we renewed our interest in pursuing development of our Device and, subsequent to our year ended December 31, 2012, we entered into an agreement with GUMI to develop a Device prototype, which was successfully completed. GUMI has completed the manufacture of several commercial models of the Device that GUMI is presently devoting resources to market under the terms of our agreement. We continue to be dependent upon the ability of GUMI to successfully market our Device, which process has started. However, we have not yet derived any revenues from GUMI's on-going marketing efforts, which commenced in late 2013 and are continuing in 2015.
We will utilize the capital we recently raised to fund OWC's business including the assembly of a professional team of highly-qualified medical and scientific experts together with experienced management and marketing executives to develop OWC's business.
Our goal is to become a leader in the research and development of cannabis-based medical drugs and treatments. To achieve our goal, we plan to focus our activities on the following areas:
Research and Development
Our research and development is focused primarily on exploring several formulations containing active compounds from the cannabis plant, including (but not exclusive to) the cannabinoids CBD and THC, and identifying potential therapeutic applications of the synergistic effects of these active compounds. The synergistic contributions of our formulations have not yet been scientifically researched and demonstrated. We aim to standardize the formulations across the extracts as a whole, not simply by reference to their key active components (CBD and/or THC).
Although there are existing reports and studies on CBD and THC, our formulations will contain several active compounds from the cannabis plant, that must be fully researched and documented in order to verify its effectiveness to indications, at what doses and which method of administration will be the most appropriate and effective.
One World Cannabis plans to produce pharmaceutical-grade cannabinoid-based products and treatments, that will be standardized in composition, formulation and dose, administered by means of an appropriate and efficient delivery system, and tested in properly controlled pre-clinical and clinical studies. OWC plans to conduct its researches, led by internationally renowned investigators, at the facilities of leading Israeli hospitals and scientific institutions. The Company will adhere to legislation, rules and guidelines regarding the investigations. Dr. Baruch, OWC's Director of Research and Regulatory Affairs, and Alon Sinai, OWC's Chief Operating Officer, will monitor the investigations and researches.
To date, OWC has signed three research collaboration and license agreements with Sheba Academic Medical Center, Tel Hashomer, Israel ("Sheba"). Sheba is a university-affiliated hospital that serves as Israel's national medical center and the most comprehensive medical center in the Middle East. Within the framework of the agreements with Sheba, OWC will initiate three studies at the Sheba facilities to explore the effect of three formulations, all based on active ingredients in the cannabis extracts, on multiple myeloma, psoriasis and fibromyalgia (a specific formulation to each indication).
At present, OWC is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015. Of course, there can be no assurance that we be able to successfully negotiate these agreements before the end of 2015, if at all.
In addition, OWC signed an R&D service agreement with G.C. Group Ltd. - an Israeli pharmaceutical R&D company, to provide formulation development services for OWC's new delivery system in the form of a cannabis dissoluble tablet. The cannabis dissoluble tablet could provide physicians with the ability to control and administrate optimal dosage, to replace the most common usage/delivery method of medical cannabis today, which is not acceptable by scientists and physicians, such as smoking, edibles and oil extracts with no adequate means of dosage control.
The Company expects to start developing other delivery system, designed for different indications, during the fourth quarter of 2015.
The Company has recently signed a Memorandum of Understanding (MoU) with Emilia Cosmetics Ltd. - a large Israeli private label manufacturer, for the developing, manufacturing and marketing of a cannabinoid-based topical cream to treat psoriasis. The Company will initiate the research and development of the topical cream by the end of the third quarter of 2015, at Emilia Cosmetics labs located in Yerucham, Israel. After the completion of the formulation development, during the fourth quarter of 2015, the Company will initiate a phase I study at the Sheba facilities to explore the effect of topical cream on psoriasis. However, we do not know if our expectations will be fulfilled in a timely manner, if at all, or that the costs of development will exceed our anticipation.
To date, One World Cannabis has filed eight provisional patents with the United States Patent and Regulatory Office (USPTO), all related to its line of activity related to cannabis-based medical products. Assuming the successful completion of the clinical trials, of which there can be no assurance, the Company believes that it will be able to retain the intellectual rights and secure patent protections.
While we retain full ownership on our intellectual property rights that we conceived prior to the signing of the research collaboration and license agreements with Sheba Academic Medical Center, the psoriasis and fibromyalgia agreements with Sheba provide that all intellectual property rights that is conceived during the course of the research is to be jointly owned by Sheba and One World Cannabis Intellectual rights related to the multiple myeloma are being negotiated and the Company expects to finalized an agreement during the 4th quarter of 2015.
Pursuant to the collaboration agreements, we are obliged to pay Sheba $330,000 for conducting the multiple myeloma trial between the 3rd quarter of 2015 and the second quarter of 2016. In addition, we expect to commence pre-clinical studies on fibromyalgia and psoriasis during 3rd quarter of 2015. Pursuant to the collaboration agreements, we are obliged to pay Sheba $300,000 during the 1st quarter of 2016 for conducting the psoriasis research, and $100,000 for the fibromyalgia research during the two years of the study. We currently have the financial resources to fund these studies, but anticipate that we will require additional funding during the next 12 months for our continuing and planned expanded operations.
Research and Development Status
The following table summarizes the stages of development for each of our current Prospect Products.
Targeted Medical Condition | Collaborator | Status |
Use of cannabis to treat multiple Myeloma | Sheba Academic Medical Center | Basic Science
Research Agreement - signed; Clinical Research Agreement - in negotiation; Pre-clinical study: Approved by Ethics Committee (IRB); In vitro tests - completed. Next: Pre-clinical study: Safety and Toxicity, PK, PD Clinical trial protocol synopsis - draft completed. |
Use of cannabis to treat Psoriasis | (1) Sheba Academic Medical Center | Research
Collaboration and License Agreement - signed; Protocol of A Phase I, double blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers - draft completed. |
Use of cannabis to treat Psoriasis | (2) Emilia Cosmetics Ltd. | Memorandum of
Understanding (MoU) for the developing, manufacturing and marketing of a
cannabinoid-based topical cream to treat psoriasis - signed; Received license to purchase and use of cannabis for R&D purposes; Formulation development will be initiated during third quarter of 2015. |
Use of cannabis to treat Fibromyalgia | Sheba Academic Medical Center | Research
Collaboration and License Agreement - signed; Clinical trial protocol synopsis - initial draft completed. |
New delivery system - cannabis dissoluble tablet | G.C. Group Ltd. | Formulation
development; Received license to purchase and use of cannabis for R&D purposed. |
Use of cannabis to treat PTSD | In Negotiations | Clinical trial documents - submitted; Awaiting for Ethics Committee (IRB) final approval. |
Use of cannabis to treat Migraine | In Negotiations | Clinical trial protocol synopsis - initial draft completed. |
OWC's Investigation on Multiple Myeloma
Dr. Merav Leiba, Head of Multiple Myeloma Outpatient Clinic and Multiple Myeloma Research Lab at Sheba's Hematology Institute, led the in vitro tests on multiple myeloma. Dr. Leiba, a specialist in Internal Medicine and Hematology, was a postdoctoral fellow at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute, Boston, Massachusetts (2006-2008). Dr. Leiba has participated in numerous clinical and investigational studies aimed at developing novel drugs for multiple myeloma.
Our in vitro tests results on multiple myeloma cells studied outside their normal biological context, on which we announced on June 17, 2015, led us to proceed with further pre-clinical study (safety and toxicity, PK, PD) of our formulation, to find out whether it has scientific merit for further development as an investigational new drug. While we are encouraged by the results of the limited in vitro tests, there can be no assurance that any clinical trial will result in commercially viable products or treatments.
Clinical trials are expensive, time consuming and difficult to design and implement. We, as well as the regulatory authorities in Israel and elsewhere, such as an IRB (Helsinki committee), IMCU - Israel Medical Cannabis Unit, or the FDA, may suspend, delay or terminate our clinical trials at any time, may require us, for various reasons, to conduct additional clinical trials, or may require a particular clinical trial to continue for a longer duration than originally planned, including, among others:
lack
of effectiveness of any formulation or delivery system during clinical trials;
discovery of serious or
unexpected toxicities or side effects experienced by trial participants or other
safety issues;
slower than
expected rates of subject recruitment and enrollment rates in clinical trials;
delays or inability in
manufacturing or obtaining sufficient quantities of materials for use in
clinical trials due to regulatory and manufacturing constraints;
delays
in obtaining regulatory authorization to commence a trial, including IRB
approvals, licenses required for obtaining and using cannabis for research,
either before or after a trial is commenced;
unfavorable
results from ongoing pre-clinical studies and clinical trials.
patients
or investigators failing to comply with study protocols;
patients
failing to return for post-treatment follow-up at the expected rate;
sites
participating in an ongoing clinical study withdraw, requiring us to engage new
sites;
third-party
clinical investigators decline to participate in our clinical studies, do not
perform them on the anticipated schedule, or act in ways
inconsistent with the investigator agreement, clinical study
protocol, good clinical practices, and other Institutional Review Board
requirements;
third-party
entities do not perform data collection and analysis in a timely or accurate
manner or at all;
regulatory
inspections of our clinical studies require us to undertake corrective action or
suspend or terminate our clinical studies;
Any of the foregoing could have a material adverse effect on our business, results of operations and financial condition.
Consulting Services
OWC believes that the complexity of the medical cannabis programs has created a demand for consulting and advisory services in different aspects of the medical cannabis industry. The Company's services are designed to help government officials, policy-makers and regulatory agencies develop and implement tailor-made comprehensive medical cannabis programs. In addition, One World Cannabis offers medical cannabis regulatory compliance services and patient-care consultancy services.
Our initial activities to secure consulting contracts will be in member states of the European Union and states of the United States that does not allow for comprehensive public medical cannabis programs.
OWC management has the expertise in designing training programs for physicians, caregivers, and researches that are essential to the establishment of a successful, patient-focused medical cannabis program. By working with policy-makers, government officials, public agencies, and privately owned businesses, we believe we can also raise the public's awareness of the benefits of cannabis-based treatments and products.
In furtherance of our plans, we may, in the future, consider strategic acquisitions and joint ventures as well as other projects to grow our business activities including but not limited to: product licensing and royalty agreements, consulting, and strategic alliances to support our Prospect Product development. However, there can be no assurance that this strategy will be successful in generating any revenues or growing out business.
Results of Operations during the three months ended June 30, 2015 as compared to the three months ended June 30, 2014
We have not generated any revenue during the three months ended June 30, 2015 and 2014. We have operating expenses related to general and administrative expenses and research and development expenses. During the three months ended June 30, 2015, we incurred a net loss of $609,427 due to general and administrative expenses of $532,815 and research and development expenses of $76,612 as compared to a net income of $106,844 due to a gain related to the cancelation of previously issued shares valued at $106,930 and interest expense of $86 during the same period in the prior year.
Our general and administrative expenses increased by $639,745 during the three-month period ended June 30, 2015 as compared to the same period in the prior year. During the three-month period ended June 30, 2015, we incurred $76,612 in research and development expenses as compared to no such expenses in the same period in the prior year.
Our comprehensive net loss during the three months ended
June 30, 2015 was
$610,077, due to
a net loss of $609,427 and $650 in
foreign currency translation adjustments as
compared to
a
comprehensive net gain of $106,844 and no foreign currency translation
adjustments in the same period in the prior year with no adjustments. Results of Operations during the
six months ended June 30, 2015 as compared to the
six months ended June 30, 2014 We have not generated any revenue during the six months ended June 30,
2015 and 2014. We have operating expenses related to general and administrative
expenses and research and development expenses. During the six months ended June
30, 2015, we incurred a net loss of $1,014,030 due to general and
administrative expenses of $824,090 and research and development expenses of
$189,940 as compared to a net loss of $402,169
due to general and
administrative expenses of $365,212, interest expenses of $2,923 and
expenses related to amortization of debt discount of $34,034. Our general and administrative expenses increased
by $458,878 or 126% during the six-month period ended June 30, 2015 as
compared to the same period in the prior year. During the six-month period
ended June 30, 2015, we incurred $189,940 in research and development expenses
as compared to no such expenses in the same period in the prior year. Our comprehensive net loss during the
six months ended June 30, 2015 was
$1,019,638, due to a net loss of $1,014,030 and $5,608 in foreign currency translation adjustments as
compared to $402,169 in the same period in the prior year with no adjustments.
Liquidity and Capital Resources
On June 30, 2015, we had current assets of $812,277 consisting of $799,374 in cash and $12,903 in other current assets. We had property and equipment valued at $28,109 as of June 30, 2015. We had total assets of $840,386 as of June 30, 2015.
We had total assets of $1,522,812 as of December 31, 2014, consisting of $1,469,267 in cash, $24,091 in other current assets and equipment valued at $29,454.
On June 30, 2015, we had $55,506 in current liabilities consisting of $52,559 in accounts payable and $2,947 in accrued expenses. On December 31, 2014, we had total liabilities of $60,304 consisting of $16,523 in accounts payable, $43,643 in accrued expenses and $138 in advances and accounts payable to related parties.
We had positive working capital of $756,771 at June 30, 2015 and $1,433,054 at December 31, 2014. Our accumulated deficits as of June 30, 2015 and December 31, 2014 were $6,907,908 and $5,893,878, respectively.
We used $751,106 in our operating activities during the six months ended June 30, 2015, which was due to a net loss of $1,014,030 offset by depreciation expenses of $4,524, shares issued for services valued at $241,170, warrants issued for services valued at $10,839, a decrease in accounts receivable of $11,188, an increase in advances and accounts payable to related parties of $138, an increase in accounts payable of $35,762 and a decrease in accrued expenses of $40,697.
We used $39,212 in our operating activities during the six months ended June 30, 2014, which was mainly due to a net loss of $402,169 offset by increases in amortization of debt discount of $34,034, non-cash compensation expenses valued at $326,000 and an increase in accounts payable and accrued liabilities by $2,950.
We used $3,179 during the six months ended June 30, 2015 to purchase property and equipment. We had no investing activities in the same period in the prior year.
Our financing activities during the six months ended June 30, 2015 provided us with $90,000 from the issuance of 800,000 shares of common stock and the recording of $50,000 in stock payable.
We financed our negative cash flow from operations during the six months ended June 30, 2014 through proceeds from issuance of common stock of $868,800 and proceeds from the issuance of notes of $14,500 representing total cash generated by financing activities of $883,300.
Based upon our cash position of $799,374 at June 30, 2015, we believe that we may need to raise additional capital, either equity or debt prior to the end of fiscal 2015 in order to fund our plan of operations including our research and development initiatives for the next twelve months. There can be no assurance, however, that additional capital will be sufficient to fund our currently anticipated expenditure requirements for the next twelve-month period nor can there be any assurance that financing will be available at satisfactory terms and conditions or at all, for that matter.
Our auditors have issued an opinion on our financial statements which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing the product. Accordingly, we must raise capital from sources other than the actual sale of the product. We must raise capital to implement our project and stay in business. Even if we raise the maximum amount of money in this offering, we do not know how long the money will last, however, we do believe it will last at least twelve months.
Our lack of operating history may make it difficult to raise capital. Our inability to borrow funds or raise equity capital to facilitate our business plan may have a material adverse effect on our financial condition and future prospects.
Funding of Our Research Programs
On October 22, 2014, we have entered into a collaboration agreement with Sheba Academic Medical Center, a hospital in Tel-Aviv, Israel, relating to the use of cannabis to treat Myeloma. Within the framework of this collaboration agreement, the Company currently conducts pre-clinical studies on multiple myeloma, which have commenced in April 2015 and we expect to commence pre-clinical studies on fibromyalgia in the third quarter of 2015. Pursuant to the agreement, we are obligated to pay Sheba $330,000 between the third quarter of 2015 and second quarter of 2016.
We are obligated to provide $300,000 in funding in the first quarter of 2016 related to the Psoriasis research conducted at Sheba. We have funding obligations of $100,000 related to the Fibromyalgia research due during two years of the studies.
Our capital expenditures allocated to our corporate activities conducted through our facilities in Petach Tikva are expected to be around $606,000 during 2015.
At present, we use our available working capital to fund these studies. However, we may need to raise additional funding prior to or if clinical studies are to commence.
Off-Balance Sheet Arrangements
As of June 30, 2015 and December 31, 2014, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities Act of 1934.
Critical Accounting Policies
Our significant accounting policies are described in the notes to our financial statements for the period ended June 30, 2015, and are included elsewhere in this registration statement.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Back to Table of ContentsNone.
ITEM 4. CONTROLS AND PROCEDURES
Back to Table of ContentsEvaluation of disclosure controls and procedures. As of June 30, 2015, the Company's chief executive officer and chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.
Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Back to Table of ContentsWe are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. However, from time to time, we may become a party to certain legal proceedings in the ordinary course of business.
Back to Table of ContentsYou should carefully consider the Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Back to Table of ContentsNone.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Back to Table of ContentsNone.
ITEM 4. MINE SAFETY DISCLOSURE.
Back to Table of ContentsNot applicable.
Back to Table of ContentsNot applicable.
Back to Table of Contents(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit No. |
Description |
---|---|
31.1 | Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CEO, Mordechi Bignitz, filed herewith. |
31.2 | Section 302 Certification of the Sarbanes-Oxley Act of 2002 of the Company's CFO, Shmuel De-Saban, filed herewith. |
32.1 | Section 906 of the Sarbanes-Oxley Act of 2002 of Mordechi Bignitz as CEO, filed herewith |
32.2 | Section 906 of the Sarbanes-Oxley Act of 2002 of Shmuel De-Saban as CFO, filed herewith |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.
Signature | Title | Date |
/s/ Mordechai Bignitz | Chief Executive Officer (Principal Executive Officer) | August 17, 2015 |
Mordechai Bignitz | ||
/s/ Shmuel De-Saban | Chief Financial Officer (Principal Financial and Principal Accounting Officer) | August 17, 2015 |
Shmuel De-Saban | ||
Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature | Title | Date |
/s/ Mordechai Bignitz | Chief Executive Officer | August 17, 2015 |
Mordechai Bignitz | ||
/s/ Mordechai Bignitz | Chairman | August 17, 2015 |
Mordechai Bignitz | ||